SG10201605729TA - Natural-killer/t-cell lymphoma (nktcl) susceptibility prediction, diagnosis and therapy - Google Patents

Natural-killer/t-cell lymphoma (nktcl) susceptibility prediction, diagnosis and therapy

Info

Publication number
SG10201605729TA
SG10201605729TA SG10201605729TA SG10201605729TA SG10201605729TA SG 10201605729T A SG10201605729T A SG 10201605729TA SG 10201605729T A SG10201605729T A SG 10201605729TA SG 10201605729T A SG10201605729T A SG 10201605729TA SG 10201605729T A SG10201605729T A SG 10201605729TA
Authority
SG
Singapore
Prior art keywords
nktcl
killer
diagnosis
therapy
natural
Prior art date
Application number
SG10201605729TA
Other languages
English (en)
Inventor
Bin Tean Teh
Soon Thye Lim
Original Assignee
Singapore Health Serv Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Singapore Health Serv Pte Ltd filed Critical Singapore Health Serv Pte Ltd
Priority to SG10201605729TA priority Critical patent/SG10201605729TA/en
Publication of SG10201605729TA publication Critical patent/SG10201605729TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G01N2333/91215—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Environmental Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
SG10201605729TA 2011-11-25 2012-11-26 Natural-killer/t-cell lymphoma (nktcl) susceptibility prediction, diagnosis and therapy SG10201605729TA (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
SG10201605729TA SG10201605729TA (en) 2011-11-25 2012-11-26 Natural-killer/t-cell lymphoma (nktcl) susceptibility prediction, diagnosis and therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SG2011088002 2011-11-25
SG10201605729TA SG10201605729TA (en) 2011-11-25 2012-11-26 Natural-killer/t-cell lymphoma (nktcl) susceptibility prediction, diagnosis and therapy

Publications (1)

Publication Number Publication Date
SG10201605729TA true SG10201605729TA (en) 2016-08-30

Family

ID=54257023

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201605729TA SG10201605729TA (en) 2011-11-25 2012-11-26 Natural-killer/t-cell lymphoma (nktcl) susceptibility prediction, diagnosis and therapy
SG11201402611WA SG11201402611WA (en) 2011-11-25 2012-11-26 Natural-killer/t-cell lymphoma (nktcl) susceptibility prediction, diagnosis and therapy

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201402611WA SG11201402611WA (en) 2011-11-25 2012-11-26 Natural-killer/t-cell lymphoma (nktcl) susceptibility prediction, diagnosis and therapy

Country Status (6)

Country Link
US (2) US20150292022A1 (ja)
EP (1) EP2782562B1 (ja)
JP (1) JP2015505669A (ja)
CN (1) CN104220051B (ja)
SG (2) SG10201605729TA (ja)
WO (1) WO2013077814A2 (ja)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6416508B2 (ja) * 2014-06-05 2018-10-31 公益財団法人がん研究会 Ｎｋ／ｔ細胞リンパ腫の検査方法
JP2020500940A (ja) * 2016-12-09 2020-01-16 オンキミューネ リミテッド 向上したｎｋ細胞ベースの治療
EP3692174A4 (en) * 2017-10-06 2021-06-23 Singapore Health Services Pte Ltd METHOD FOR TREATMENT OF LYMPHOMAS
CN108841869B (zh) * 2018-05-31 2022-05-06 上海交通大学医学院附属瑞金医院 一种斑马鱼nk/tcl肿瘤模型的构建方法及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE369844T1 (de) * 2000-01-24 2007-09-15 Genzyme Corp Inhibitoren des jak/stat-weges und deren verwendung zur behandlung von allgemeiner primärer osteoarthritis
AU2007207516A1 (en) * 2006-01-20 2007-07-26 Oregon Health And Science University Mutant JAK3 kinase in human leukemia

Also Published As

Publication number Publication date
SG11201402611WA (en) 2014-06-27
EP2782562B1 (en) 2016-12-21
US20150292022A1 (en) 2015-10-15
JP2015505669A (ja) 2015-02-26
CN104220051A (zh) 2014-12-17
CN104220051B (zh) 2017-04-19
WO2013077814A3 (en) 2013-10-10
EP2782562A2 (en) 2014-10-01
WO2013077814A2 (en) 2013-05-30
US10378062B2 (en) 2019-08-13
US20170029899A1 (en) 2017-02-02

Similar Documents

Publication Publication Date Title
IL222778A0 (en) Diabetes therapy
EP2596741A4 (en) ENDOSCOPE AND TREATMENT INSTRUMENT FOR AN ENDOSCOPE
EP2779523A4 (en) RECHIFFING SYSTEM, RECHIFFING DEVICE AND PROGRAM
GB2487355B (en) Processing apparatus, trace unit and diagnostic apparatus
EP2626000A4 (en) ENDOSCOPADAPTER, ENDOSCOPIC PROCESSOR AND ENDOSCOPY SYSTEM
EP2606811A4 (en) FLEXION OPERATION DEVICE FOR ENDOSCOPE, AND ENDOSCOPE
EP2713879A4 (en) ANALYTE DETECTOR DEVICES, CONNECTIONS, AND METHODS
EP2611496A4 (en) Methods of Treatment
EP2757885A4 (en) CHEMICAL ENTITIES, COMPOSITIONS, AND SPECIFIC METHODS
EP2825649A4 (en) SELECTIVE CELL TARGETING USING ADENOVIRUS AND CHEMICAL SIZE
PT2621569T (pt) Dispositivo de tratamento
EP2501125A4 (en) IMAGING DEVICE, IMAGING MEANS, AND PROGRAM
AP2014007420A0 (en) Integrated portable medical diagnostic system
EP2586495A4 (en) BREATHING DEVICE, BREATHING PROGRAM AND PARTICLE BEAM THERAPY DEVICE
EP2652506A4 (en) USE OF ANTIBODIES AGAINST CXCL16 AND CXCR6 FOR TREATMENT OR FOR THE DETECTION OF CANCER
EP2669639A4 (en) DISPLAY ELEMENT, DISPLAY UNIT AND DISPLAY INSTRUMENT
HK1182444A1 (en) Biosensor
ZA201205425B (en) Treatment with vb-201
EP2621497A4 (en) ASSOCIATION TREATMENT FOR ROSE ACNE
EP2555036A4 (en) ENDOSCOPIC DEVICE AND CONNECTION UNIT FOR ENDOSCOPE DEVICE
EP2737842A4 (en) LOCATION DETECTION DEVICE, CAPSULE DOSCOPY SYSTEM AND PROGRAM FOR DETECTING THE PLACE OF A CAPSULE ENDOSCOPE
EP2415408A4 (en) TREATMENT DEVICE
GB2482171B (en) Catalyst treatment
AP2013006855A0 (en) Medical device
SG10201601853XA (en) Pericyte progenitors from peripheral blood